Table 1.
Clinical and molecular variables in eGBM adjusted for various related CNS tumor clusters.
| Variable | Clustered with PXA (n = 38) | Clustered with adult IDHwt GBM (n = 17) | Clustered with pediatric RTK1 GBM (n = 9) |
|---|---|---|---|
| Median age | 17 | 50 | 18 |
| Children* | 55% | 0 | 56% |
| Gender M vs. F | 58%/42% | 94%/6% | 56%/44% |
| PXA‐like foci | 34% | 24% | 22% |
| Median OS | 34 months | 11 months | 18 months |
| Mean MIB1 LI | 47% | 53% | 48% |
| Amplifications | 0 | 25% | 89% |
| CDKN2A homo del | 61% | 53% | 33% |
| 7 gain | 53% | 88% | 30% |
| 10q loss | 28% | 88% | 70% |
| BRAF V600E mut | 79% | 35% | 0 |
| pTERT mut | 30% | 83% | 0 |
| MGMT methyl | 21% | 47% | 33% |
| Chromothripsis | 0 | 0 | 100% |
*Childhood defined as <18 years of age.
Abbreviations: M = male; F = female; OS = overall survival; LI = labeling index; Homo del = homyzygous deletion; Mut = mutation; Methyl = promoter region methylation.